Jpmorgan Chase & CO Actinium Pharmaceuticals, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ATNM
# of Institutions
75Shares Held
8.32MCall Options Held
65.2KPut Options Held
21.7K-
Black Rock Inc. New York, NY1.88MShares$2.72 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.63MShares$2.36 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA686KShares$994,9210.0% of portfolio
-
State Street Corp Boston, MA603KShares$873,8410.0% of portfolio
-
Acadian Asset Management LLC Boston, MA454KShares$657,8560.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $36.5M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...